Shares of I-Mab (IMAB) is currently trading at $79.17, up $7.47 or 10.43%, with trading volume of 208K versus an average volume of 587K shares. The stock has been trading between $32.64 and $85.40 for the past one year.
This clinical stage biopharmaceutical company I-Mab, on September 2, 2021, said it has been added to FTSE Global Equity Index Series, following FTSE's most recent semi-annual review. These inclusions will become effective after the market close on Friday, September 17, 2021.
Last month, I-Mab announced positive interim data from its U.S. phase 2/3 study of plonmarlimab for the treatment of cytokine release syndrome or CRS in patients with severe COVID-19.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.